Australia markets closed

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
8.550.00 (0.00%)
At close: 3:52PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.55
Open8.82
Bid0.00 x 0
Ask0.00 x 0
Day's range8.55 - 8.55
52-week range8.55 - 33.48
Volume400
Avg. volume77
Market cap396.823M
Beta (5Y monthly)2.14
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

    Cytovia Commits to Additional Milestones and Equity grantAVENTURA, Fla. and NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK (NK cells derived from iPSC) and CAR (Chimeric Antigen Receptor) Natural Killer (NK) cells derived from induced pluripotent stem cells (iPSCs) and Flex-NK™ cell engager multifunctional antibodies, and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage g

  • GlobeNewswire

    Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

    NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage gene-editing company employing its core technology to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR-)T cells in the field of immuno-oncology and gene-edited hematopoietic stem cells in other indications, announced the first preclinical data on UCARTMESO, its allogeneic CAR-T cell product candidate targeting mes

  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights10/31/202145,475,31051,076,779 About CellectisCellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-sh